Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

New England Journal of Medicine

Volumn 357, Issue 21, 2007, Pages 2133-2142

  Weber, Donna M ^a   Chen, Christine ^b   Niesvizky, Ruben ^c   Wang, Michael ^a   Belch, Andrew ^d   Stadtmauer, Edward A ^e   Siegel, David ^f   Borrello, Ivan ^g   Rajkumar, S Vincent ^h   Chanan Khan, Asher Alban ⁱ   Lonial, Sagar ^j   Yu, Zhinuan ^k   Patin, John ^k   Olesnyckyj, Marta ^k   Zeldis, Jerome B ^k   Knight, Robert D ^k  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j EMORY UNIVERSITY   (United States)

^k CELGENE CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANADA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; INFESTATION; INSOMNIA; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NORTH AMERICA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

EID: 36349010285     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa070596     Document Type: Article

References (15)

1. American Cancer Society. Cancer facts and figures 2005. Atlanta: American Cancer Society, 2005.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71. [Erratum, N Engl J Med 2000;342:364.]
3. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
4. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
5. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
6. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
7. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
8. Zangari MTG, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (mm) patients who relapse after high dose chemotherapy (HDCT). Blood 2001;98:775a. abstract.
9. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
10. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
11. National Cancer Institute. Common toxicity criteria v2.0 (CTC). (Accessed October 26, 2007, at http://ctep.cancer.gov/reporting/ctc_archive.html.)
12. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
13. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
14. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2007;25:Suppl:18S. abstract.
15. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108:403.